MaryAnn Morgan-Cox is a Sr Director and Leader of the Immunology Design Hub at Eli Lilly and Company, where she focuses on innovative approaches to drug development, clinical research, commercialization, and portfolio management.

Dr. Buxton is CEO of Global Coalition for Adaptive Research (GCAR), a nonprofit organization founded to expedite the discovery and development of treatments for patients with rare and deadly diseases, and home of several Phase II/III adaptive platform trials for drug registration. Dr. Buxton has been involved in clinical research and drug development for over 20 years. She has been instrumental in the establishment of numerous innovative clinical research programs, with extensive experience in building and running master protocols. Focused on efficient approaches to the design and execution of clinical trials, Dr. Buxton brings expertise in scientific and operational implementation, regulatory strategy, and partnership development.

Mitzi Allred is a Director at MSD where her focus is on Structured Content Management. She has over 20 years of experience in the biopharmaceutical industry in Regulatory & Clinical Operations. Mitzi uses process improvement through information design and structured content reuse to leverage time. quality and efficiency for content within documents . Over the last fifteen years, she has led improvements in electronic documents, structured content management reuse implementations. Mitzi participates in the TransCelerate Clinical Content & Reuse workstream and ICH M11 Working group. Additionally, Mitzi has PhD in engineering and 15 years of experience in Aerospace.

Karen received her Ph.D. in Statistics from Baylor University in 2001, and joined Eli Lilly and Company at that time. She is currently Research Fellow at Eli Lilly and Company where she leads the Statistical Innovation Center, a team that focuses on innovative design and analysis of clinical trials. In 2011, Karen helped form and led the DIA Bayesian Scientific Working Group and currently serves as past-chair. This group includes members in Industry, Regulatory, and Academia. Her research interests include Bayesian design and analysis of clinical trials and master protocols. In 2016, Karen was elected a Fellow of the American Statistical Association.